Findings of Research Misconduct, 53303-53304 [2010-21579]

Download as PDF Federal Register / Vol. 75, No. 168 / Tuesday, August 31, 2010 / Notices conflict with a fundamental economic purpose of ARRA, which is to create or retain jobs. The Municipal Assistance Unit (CMU) has reviewed this waiver request and has determined that the supporting documentation provided by Sturbridge establishes both a proper basis to specify a particular manufactured good, and that the domestic manufactured goods that are currently available do not meet the design specifications for the proposed project. The information provided is sufficient to meet the following criteria listed under Section 1605(b) of the ARRA and in the April 28, 2009 Memorandum: Iron, steel, and the manufactured goods are not produced in the United States in sufficient and reasonably available quantities and of a satisfactory quality. The March 31, 2009 Delegation of Authority Memorandum provided Regional Administrators with temporary authority to issue exceptions to Section 1605 of the ARRA within the geographic boundaries of their respective regions and with respect to requests by individual grant recipients. Having established both a proper basis to specify the particular good required for this project and that this manufactured good was not available from a producer in the United States, the Town of Sturbridge, Massachusetts is hereby granted a waiver from the Buy American requirements of Section 1605(a) of Public Law 111–5. This waiver permits use of ARRA funds for the purchase of a foreign manufactured submersible mixer in Sturbridge’s waiver request submittal dated May 25, 2010. This supplementary information constitutes the detailed written justification required by Section 1605(c) for waivers based on a finding under subsection (b). Authority: Pub. L. 111–5, section 1605. Dated: August 19, 2010. Ira W. Leighton, Acting Regional Administrator, EPA Region 1—New England. Date and Time: The regular meeting of the Board will be held at the offices of the Farm Credit Administration in McLean, Virginia, on September 8, 2010, from 9 a.m. until such time as the Board concludes its business. DATES: FOR FURTHER INFORMATION CONTACT: Roland E. Smith, Secretary to the Farm Credit Administration Board, (703) 883– 4009, TTY (703) 883–4056. ADDRESSES: Farm Credit Administration, 1501 Farm Credit Drive, McLean, Virginia 22102–5090. SUPPLEMENTARY INFORMATION: Parts of this meeting of the Board will be open to the public (limited space available), and parts will be closed to the public. In order to increase the accessibility to Board meetings, persons requiring assistance should make arrangements in advance. The matters to be considered at the meeting are: Open Session A. Approval of Minutes • August 12, 2010. B. New Business • Merger of the Louisiana Ag Credit ACA, and Subsidiaries with Southern AgCredit, ACA, and Subsidiaries. • Fall 2010 Abstract of the Unified Agenda of Federal Regulatory and Deregulatory Actions and Fall 2010 Regulatory Performance Plan. • Farm Credit Administration Revised FY 2011 and Proposed FY 2012 Budget. Closed Session* • OSMO Quarterly Report. *Session Closed—Exempt pursuant to 5 U.S.C. 552b(c)(8) and (9). Dated: August 27, 2010. Roland E. Smith, Secretary, Farm Credit Administration Board. [FR Doc. 2010–21859 Filed 8–27–10; 4:15 pm] BILLING CODE 6705–01–P FINANCIAL CRISIS INQUIRY COMMISSION Notice of Public Hearing srobinson on DSKHWCL6B1PROD with NOTICES FARM CREDIT ADMINISTRATION Financial Crisis Inquiry Commission. ACTION: Notice. AGENCY: Farm Credit Administration Board; Sunshine Act; Regular Meeting AGENCY: Farm Credit Administration. SUMMARY: Notice is hereby given, VerDate Mar<15>2010 16:33 Aug 30, 2010 Jkt 220001 The next public hearing of the Financial Crisis Inquiry Commission (FCIC) is titled ‘‘Too Big to Fail: Expectations and Impact of Extraordinary Government Intervention and the role of Systemic Risk in the SUMMARY: pursuant to the Government in the Sunshine Act (5 U.S.C. 552b(e)(3)), of the regular meeting of the Farm Credit Administration Board (Board). PO 00000 Frm 00033 Fmt 4703 Financial Crisis.’’ The forum will also be webcast live at https://www.FCIC.gov. DATES: The hearing will be held on: Wednesday, September 1, 2010, 9 a.m. EDT; and Thursday, September 2, 2010, 9 a.m. EDT. ADDRESSES: The hearing will be held at: Dirksen Senate Office Building, Room 538, Washington, DC 20515. FOR FURTHER INFORMATION CONTACT: Gretchen Kinney Newsom, Financial Crisis Inquiry Commission, 1717 Pennsylvania Avenue, Suite 800, Washington, DC 20006. 202–292–2799; 202–632–1604 fax. SUPPLEMENTARY INFORMATION: The purpose of the Financial Crisis Inquiry Commission is to examine the causes, domestic and global, of the current financial and economic crisis in the United States, per the requirements of the Fraud Enforcement and Recovery Act of 2009 (‘‘FERA’’), Section 5, Public Law 111–21–123 Stat. 1617 (2009). Public Participation: The hearing is open to the public. The Chairman of the Commission will lead the hearing for the orderly conduct of business. Dated: August 25, 2010. Gretchen Kinney Newsom, Certifying Official and Special Assistant to the Chairman, Financial Crisis Inquiry Commission. [FR Doc. 2010–21613 Filed 8–30–10; 8:45 am] BILLING CODE 6820–RK–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Reports [FR Doc. 2010–21676 Filed 8–30–10; 8:45 am] BILLING CODE 6560–50–P 53303 Sfmt 4703 Findings of Research Misconduct Office of the Secretary, HHS. Notice. AGENCY: ACTION: Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case: Hung-Shu Chang, PhD, Washington State University: Based on the report of an investigation conducted by the Washington State University (WSU) and additional analysis by ORI in its oversight review, the U.S. Public Health Service (PHS) found that Hung-Shu Chang, PhD, former postdoctoral fellow, WSU, engaged in research misconduct in research supported by National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), grant R01 ES012974. PHS found that the Respondent engaged in scientific (42 CFR 50.102) and research misconduct by fabricating SUMMARY: E:\FR\FM\31AUN1.SGM 31AUN1 53304 Federal Register / Vol. 75, No. 168 / Tuesday, August 31, 2010 / Notices and falsifying data in Figure 3 of a paper published in Endocrinology.1 Specifically, PHS found that: • Respondent, by not conducting any of the claimed bisulfite sequencing, fabricated the methylation status of CpG sites in eight candidate genes identified in both Figures 3 and 4 as No. 11, No. 12, No. 13, No. 14, 15, No. 22, No. 26, No. 31, and No. 19, to support the hypothesis that the environmental compound, vinclozolin, induces a permanent alteration in the epigenetic reprogramming of the germline that promotes transgenerational disease states. • Respondent, by conducting only a small fraction of the claimed bisulfite sequencing, and falsifying the results obtained, falsified the methylation status of CpG sites in eight additional candidate genes, identified in Figures 3 and 4 as No. 2, 3, 24, No. 5, 6, 9, No. 8, No. 16, No. 17, 18, No. 27, 28, No. 29, and No. 33. Dr. Chang has entered into a Voluntary Settlement Agreement in which he has voluntarily agreed, for a period of three (3) years, beginning on July 21, 2010: (1) To exclude himself from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; (2) that any institution that submits an application for PHS support for a research project on which the Respondent’s participation is proposed or that uses him in any capacity on PHS-support research, or that submits a report of PHS-funded research in which the Respondent is involved, must concurrently submit a plan for supervision of the Respondent’s duties to the funding agency for approval. The supervisory plan must be designed to ensure the scientific integrity of the Respondent’s research contribution while applying for or conducting PHSsupported research. Respondent agrees to ensure that a copy of the supervisory plan is submitted to ORI by the institution for ORI approval. Respondent agrees not to participate in any PHS-supported research until such a supervisory plan is submitted to ORI. srobinson on DSKHWCL6B1PROD with NOTICES FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative Oversight, Office of Research Integrity, 1 Chang, H.S., Anway, M.D., Rekow, S.S., & Skinner, M.K. ‘‘Transgenerational epigenetic imprinting of the male germline by endocrine disruption exposure during gonadal sex determination.’’ Endocrinology 147(12):5524–5541; hereafter referred to as the ‘‘Endocrinology paper.’’ VerDate Mar<15>2010 16:33 Aug 30, 2010 Jkt 220001 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8800. John Dahlberg, Director, Division of Investigative Oversight, Office of Research Integrity. [FR Doc. 2010–21579 Filed 8–30–10; 8:45 am] BILLING CODE 4150–31–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Office of the Assistant Secretary for Health; Statement of Organization, Functions, and Delegations of Authority Part A, Office of the Secretary, Statement of Organizations, Functions and Delegations of Authority for the Department of Health and Human Services (HHS) is being amended at Chapter AA, ‘‘Immediate Office of the Secretary,’’ which was last amended at 75 FR 20364–65, dated April 19, 2010, and at Chapter AC, ‘‘Office of Public Health and Science (OPHS),’’ which was last amended at 72 FR 58095–96, dated October 12, 2007. This amendment will accomplish two tasks: (1) In Chapter AC, revise the title of the office headed by the Assistant Secretary for Health (ASH) from the ‘‘Office of Public Health and Science’’ to the ‘‘Office of the Assistant Secretary for Health,’’ and; (2) add information about a new office reporting to the Assistant Secretary for Health (ASH), the ‘‘Office of Adolescent Health,’’ established in section 1708 of the Public Health Service (PHS) Act (42 U.S.C. 300u–7), and most recently addressed in the December 8, 2009, Conference Report (House Report 111– 366) accompanying the Consolidated Appropriations Act, 2010 (Pub. L. 111– 117). The changes are as follows: A. Under Part A, Chapter AA, Section AA.10 Organization, replace the ‘‘Office of Public Health and Science (AC)’’ with the ‘‘Office of the Assistant Secretary for Health (AC).’’ B. Under Part A generally and Part A, Chapter AC, replace all references to the ‘‘Office of Public Health and Science’’ with the ‘‘Office of the Assistant Secretary for Health’’ and all references to ‘‘OPHS’’ with ‘‘OASH.’’ C. Under Part A, Chapter AC, Section AC.10 Organization, insert ‘‘M. Office of Adolescent Health (ACR)’’ immediately after ‘‘L. Office of Commissioned Corps Force Management (ACQ).’’ D. Under Part A, Chapter AC, Section AC.20 Functions, insert the following text immediately after item, ‘‘L. Office of Commissioned Corps Force Management (ACQ)’’: PO 00000 Frm 00034 Fmt 4703 Sfmt 4703 M. Office of Adolescent Health (ACR) Section ACR.00 Mission. The Director of the Office of Adolescent Health (OAH) is the principal advisor to the Assistant Secretary for Health (ASH) on health-related policy and program issues related to adolescents. These issues cut across Health and Human Services (HHS) components which provide research, services, prevention, promotion, treatment, training, education, and information dissemination related to adolescent health. OAH is responsible for implementing activities authorized by section 1708 of the Public Health Service (PHS) Act. Section ACR.10 Organization. The Office of Adolescent Health is headed by a Director who reports to the Assistant Secretary for Health and is includes the following components: A. Immediate Office of the Director (ACR) B. Division of Program Development and Operations (ACR1) C. Division of Policy, Planning, and Communications (ACR2) Section ACR.20 Functions 1. Immediate Office of the Director (ACR). The Immediate Office of the Director (IOD) plans and directs financial management and policy development, including budget formulation and execution. The IOD also oversees legislative activities related to adolescent health, acts as a liaison on personnel management to the Office of the Assistant Secretary for Health (OASH) and the Program Support Center, and coordinates correspondence control and executive secretariat functions for OAH. The IOD also manages the day-to-day operations of OAH, plans, coordinates, monitors, and evaluates OAH grants and contracts, and ensures the appropriate exercise of delegated authorities and responsibilities. 2. Division of Program Development and Operations (ACR1). The Division of Program Development and Operations (DPDO) advises the OAH Director on the development of new programs and policies, oversees the implementation and administration of competitive grants and cooperative agreements, monitors grantee activities, evaluates the focus and impact of ongoing programs, prepares analytical reports on program trends, provides training and technical assistance for grant programs, and assesses performance of grantee operations. The Division manages the development of funding announcements and contract scopes of work and the review and award of program grants, E:\FR\FM\31AUN1.SGM 31AUN1

Agencies

[Federal Register Volume 75, Number 168 (Tuesday, August 31, 2010)]
[Notices]
[Pages 53303-53304]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-21579]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) and the Assistant Secretary for Health have taken final action in 
the following case:
    Hung-Shu Chang, PhD, Washington State University: Based on the 
report of an investigation conducted by the Washington State University 
(WSU) and additional analysis by ORI in its oversight review, the U.S. 
Public Health Service (PHS) found that Hung-Shu Chang, PhD, former 
postdoctoral fellow, WSU, engaged in research misconduct in research 
supported by National Institute of Environmental Health Sciences 
(NIEHS), National Institutes of Health (NIH), grant R01 ES012974.
    PHS found that the Respondent engaged in scientific (42 CFR 50.102) 
and research misconduct by fabricating

[[Page 53304]]

and falsifying data in Figure 3 of a paper published in 
Endocrinology.\1\ Specifically, PHS found that:
---------------------------------------------------------------------------

    \1\ Chang, H.S., Anway, M.D., Rekow, S.S., & Skinner, M.K. 
``Transgenerational epigenetic imprinting of the male germline by 
endocrine disruption exposure during gonadal sex determination.'' 
Endocrinology 147(12):5524-5541; hereafter referred to as the 
``Endocrinology paper.''
---------------------------------------------------------------------------

     Respondent, by not conducting any of the claimed bisulfite 
sequencing, fabricated the methylation status of CpG sites in eight 
candidate genes identified in both Figures 3 and 4 as No. 11, No. 12, 
No. 13, No. 14, 15, No. 22, No. 26, No. 31, and No. 19, to support the 
hypothesis that the environmental compound, vinclozolin, induces a 
permanent alteration in the epigenetic reprogramming of the germline 
that promotes transgenerational disease states.
     Respondent, by conducting only a small fraction of the 
claimed bisulfite sequencing, and falsifying the results obtained, 
falsified the methylation status of CpG sites in eight additional 
candidate genes, identified in Figures 3 and 4 as No. 2, 3, 24, No. 5, 
6, 9, No. 8, No. 16, No. 17, 18, No. 27, 28, No. 29, and No. 33.
Dr. Chang has entered into a Voluntary Settlement Agreement in which he 
has voluntarily agreed, for a period of three (3) years, beginning on 
July 21, 2010:
    (1) To exclude himself from serving in any advisory capacity to 
PHS, including but not limited to service on any PHS advisory 
committee, board, and/or peer review committee, or as a consultant;
    (2) that any institution that submits an application for PHS 
support for a research project on which the Respondent's participation 
is proposed or that uses him in any capacity on PHS-support research, 
or that submits a report of PHS-funded research in which the Respondent 
is involved, must concurrently submit a plan for supervision of the 
Respondent's duties to the funding agency for approval. The supervisory 
plan must be designed to ensure the scientific integrity of the 
Respondent's research contribution while applying for or conducting 
PHS-supported research. Respondent agrees to ensure that a copy of the 
supervisory plan is submitted to ORI by the institution for ORI 
approval. Respondent agrees not to participate in any PHS-supported 
research until such a supervisory plan is submitted to ORI.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative 
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 
750, Rockville, MD 20852, (240) 453-8800.

John Dahlberg,
Director, Division of Investigative Oversight, Office of Research 
Integrity.
[FR Doc. 2010-21579 Filed 8-30-10; 8:45 am]
BILLING CODE 4150-31-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.